A personalized DNA vaccine for glioblastoma, an aggressive and incurable brain cancer, appears safe and shows early signs of ...
A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for ...
A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.
Glioblastoma vaccine shows promise by activating immune response and improving survival in a phase 1 trial at Siteman Cancer Center.
MedPage Today on MSN
Personalized DNA Vaccine Shows Promise in Brain Cancer
Survival rate surpasses historical outcomes in a small phase I study ...
Morning Overview on MSN
New combination therapy achieves unprecedented remission in glioblastoma brain cancer models
Glioblastoma is the most aggressive primary brain cancer in adults, killing most patients within two years of diagnosis ...
Scientists are creating a glioblastoma 'tumor on a chip'—a tiny living system capable of mimicking the key features of the ...
12/16 newly diagnosed GBM patients remain alive with no attributable serious adverse events at average of 12.9 months of follow up. Current 12-month overall survival of 88% for unmethylated GBM ...
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...
Mid-Michigan NOW on MSN
8th annual Cars for Cancer to spread awareness of deadly type of brain cancer
DURAND, Mich.
A personalized vaccine to treat glioblastoma, a fast-growing and incurable brain cancer that affects four in 100,000 people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results